FURTHER ANALYSES HIGH LIGHT BENEFITS OF PARP INHIBITORS AS FRONTLINE MAINTENANCE IN OVARIAN CANCER.

Citation metadata

Author: Kevin Wright
Date: May 2020
From: Oncology(Vol. 34, Issue 5)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 590 words
Lexile Measure: 1260L

Document controls

Main content

Article Preview :

Evidence for maintenance treatment with PARP inhibitors as the standard of care in the frontline setting for patients with ovarian cancer continues to mount, according to additional analyses from the phase 3 PRIMA trial and the phase 3 PAOLA-1 trial released as part of the virtual platform for the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women's Cancer.

BRCA and HRD status in the PRIMA Trial

As its primary end point, the phase 3 PRIMA trial demonstrated that frontline maintenance with niraparib (Zejula) improved median progression-free survival (PFS) by 5.6 months compared with placebo (13.8 vs 8.2 months; HR for disease progression or death, 0.62; 95% CI, 0.50-0.76; P <.001). (1)

As part of that analysis, investigators looked at homologous recombination deficiency (HRD) and BRCA status as key biomarkers of PFS. Of the 733 randomized patients, 373 (51%) had tumors with HRD, while 249 (34%)...

Source Citation

Source Citation   

Gale Document Number: GALE|A677572598